Immune reconstitution inflammatory syndrome after withdrawal of natalizumab?
Lenhard
T
T
Division of Molecular Neuroimmunology, Department of Neurology, University Hospital Heidelberg, INF 400, D-69120 Heidelberg, Germany.
Biller
A
A
Mueller
W
W
Metz
I
I
Schönberger
J
J
Wildemann
B
B
D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D005260:Female; D006801:Humans; D054019:Immune Reconstitution Inflammatory Syndrome / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology; D020529:Multiple Sclerosis, Relapsing-Remitting / Q000188:drug therapy / Q000473:pathology; D000069442:Natalizumab; D013375:Substance Withdrawal Syndrome / Q000175:diagnosis* / Q000209:etiology / Q000473:pathology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000069442:Natalizumab